Suggestions
Jack Scannell
CEO, Etheros Pharmaceuticals Corp.
Jack Scannell is the Chief Executive Officer of Etheros Pharmaceuticals, a position he has held since October 2021. Based in Delaware, United States, Scannell is known for his focus on "predictive validity" in drug research and development (R&D), emphasizing its importance for improving the drug development process.
Professional Background
-
Founder of JW Scannell Analytics Ltd.: Since August 2014, he has been involved in analytics related to drug development.
-
Honorary Fellow: He is associated with the School of Social and Political Science at the University of Edinburgh, contributing to research on the influences of regulation and economics on R&D for new antimicrobial drugs and diagnostics.
-
Previous Roles:
- Co-head of Pharmaceuticals - Equity Research at UBS (2016-2019): Focused on European drug and biotech stocks.
- Head of Discovery Research at e-Therapeutics PLC (2013-2014): Engaged in early-stage drug discovery.
- Management Consultant at Boston Consulting Group (2000-2005).
- University Lecturer at Newcastle University (1995-1999): Specialized in systems neuroscience and mathematical biology.
Scannell's extensive experience in pharmaceuticals and biotechnology, combined with his academic involvement, positions him as a significant figure in the industry, particularly in discussions around drug R&D productivity and innovation.1
